Skip to main content

Peer Review reports

From: Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

Original Submission
12 Sep 2019 Submitted Original manuscript
6 Oct 2019 Reviewed Reviewer Report - CIBELE BORGES
7 Oct 2019 Reviewed Reviewer Report - Marcello Ciaccio
18 Oct 2019 Author responded Author comments - Milana Bergamino Sirvén
Resubmission - Version 2
18 Oct 2019 Submitted Manuscript version 2
23 Oct 2019 Author responded Author comments - Milana Bergamino Sirvén
Resubmission - Version 3
23 Oct 2019 Submitted Manuscript version 3
Publishing
25 Oct 2019 Editorially accepted
21 Nov 2019 Article published 10.1186/s40360-019-0367-x

You can find further information about peer review here.

Back to article page